Drug-Eluting Stents

Global Drug-Eluting Stents Market to Reach US$11.7 Billion by 2030

The global market for Drug-Eluting Stents estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Polymer-Free, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Polymer-based segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.5% CAGR

The Drug-Eluting Stents market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Drug-Eluting Stents Market - Key Trends and Drivers Summarized

What Are Drug-Eluting Stents and How Do They Function?

Drug-eluting stents (DES) are specialized medical devices used to treat coronary artery disease (CAD), a condition characterized by the narrowing of coronary arteries due to plaque buildup. These stents are tiny mesh tubes coated with medication that is gradually released to prevent the artery from becoming blocked again, a process known as restenosis. The structure of a drug-eluting stent includes a metal scaffold to provide mechanical support to the artery, and a polymer coating that controls the release of the drug over time. The drug inhibits cell proliferation and reduces inflammation, which are critical factors in preventing restenosis. By combining mechanical and pharmacological approaches, DES offer a significant improvement over bare-metal stents (BMS), which only provide structural support and are associated with higher rates of restenosis.

How Have Technological Advancements Improved Drug-Eluting Stents?

The field of drug-eluting stents has seen remarkable technological advancements that have enhanced their efficacy and safety profiles. Innovations in stent design, such as thinner struts and more flexible materials, have improved the deliverability and conformability of the stents, allowing for easier navigation through complex arterial pathways. The development of biodegradable polymers, which gradually dissolve after delivering the drug, has reduced long-term complications associated with permanent polymer residues. Advances in drug formulations have also played a crucial role, with newer drugs offering better control over cell proliferation and inflammation. Imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further refined the deployment process by providing real-time, high-resolution images of the arteries, ensuring precise placement and optimal expansion of the stents. These technological improvements collectively contribute to better patient outcomes, reducing the incidence of adverse events and the need for repeat interventions.

What Are the Clinical Applications and Benefits of Drug-Eluting Stents?

Drug-eluting stents are primarily used in the treatment of coronary artery disease, but their applications extend to other vascular conditions as well. They are employed in the management of peripheral artery disease (PAD), where they help to open narrowed arteries in the legs, enhancing blood flow and reducing symptoms like pain and fatigue. The use of DES in treating complex lesions, such as those in patients with diabetes or multivessel disease, has shown promising results, offering a safer and more effective alternative to surgical interventions. The primary benefits of DES include a lower risk of restenosis and reduced need for repeat revascularization procedures, leading to improved long-term patient outcomes. Additionally, the minimally invasive nature of stent implantation, combined with shorter hospital stays and faster recovery times compared to open-heart surgery, makes DES a preferred option for many patients and healthcare providers.

What Drives the Growth in the Drug-Eluting Stents Market?

The growth in the drug-eluting stents market is driven by several factors, including technological advancements, increasing prevalence of cardiovascular diseases, and expanding healthcare infrastructure. The rising incidence of coronary artery disease, partly due to lifestyle changes and an aging population, is significantly boosting the demand for effective treatment options like DES. Advances in stent technology, such as the development of next-generation stents with enhanced biocompatibility and drug delivery mechanisms, are propelling market growth. Additionally, the growing preference for minimally invasive procedures among patients and healthcare providers is driving the adoption of DES over traditional surgical methods. Regulatory approvals and favorable reimbursement policies are also playing a crucial role in expanding the market reach. Furthermore, increasing investments in research and development by key industry players and the expansion of healthcare facilities in emerging markets are creating new opportunities for growth. The integration of advanced imaging technologies with stent deployment procedures is improving clinical outcomes, further strengthening the case for DES in cardiovascular treatment protocols. These factors, combined with a greater awareness of heart health and proactive management of cardiovascular conditions, are driving the robust growth of the drug-eluting stents market.

SCOPE OF STUDY:

The report analyzes the Drug-Eluting Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Coating (Polymer-Free, Polymer-based); Application (Coronary Artery Disease, Peripheral Artery Disease); End-Use (Cardiology Centers, Ambulatory Surgery Centers, Hospitals)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• Abbott Laboratories
• AlviMedica
• Arterius Limited
• Biotronik SE
• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• STENTYS SA
• Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.